Reticuloendothelial system cell phagocytosis of nanoparticles (RES cell phagocytosis (RES))

The reticuloendothelial system refers collectively to a network of specialized phagocytic cells, including monocytes, macrophages, Kupffer cells in the liver, splenic macrophages, and scavenger endothelial cells. These cells play an essential role in clearing foreign particles—including therapeutic nanoparticles—from the bloodstream through phagocytosis. This function is crucial for maintaining blood homeostasis and defending against pathogens but presents a significant barrier for nanoparticle-based drug delivery systems because rapid uptake by these cells can limit drug bioavailability at intended targets. Strategies have been developed in nanomedicine—such as surface modification with polyethylene glycol ("PEGylation") or use of CD47-derived peptides—to mask nanoparticles from recognition by these phagocytes. Such approaches aim either to prolong circulation time or selectively block RES-mediated clearance without broadly suppressing immune function. However, manipulating this pathway must be carefully balanced due to risks like altered immune responses and potential toxicity. Importantly, "reticuloendothelial_system_cells_phagocytosis_of_nanoparticles" does not refer to any single molecular target but rather describes an aggregate physiological process involving multiple cell types within the reticuloendothelial/mononuclear phagocyte systems. As such, it should not be considered a canonical therapeutic target like receptors or enzymes but rather an important biological barrier influencing pharmacokinetics and biodistribution in nanomedicine applications.

Other names

Reticuloendothelial systemMononuclear phagocyte system (MPS)RESPhagocytic clearance by RES cellsMacrophage-mediated nanoparticle clearance

Drugs do not act on this as a direct target; however, strategies such as PEGylation or CD47-mimetic peptides are used to reduce recognition and uptake by these cells.